Provider Briefing: Podofilox Supply in 2026

If your patients have been reporting difficulty filling Podofilox (Condylox) prescriptions, the issue is real and ongoing. As of early 2026, Podofilox — one of the most commonly prescribed patient-applied treatments for external genital warts — continues to face intermittent supply disruptions across the United States.

This briefing covers the current timeline, prescribing implications, alternatives, cost considerations, and tools you can use to help your patients access treatment more efficiently.

Timeline: How We Got Here

Podofilox supply has been inconsistent for several years, driven by structural factors in the generic pharmaceutical market:

• Limited manufacturer base: Only a small number of companies produce generic Podofilox 0.5% topical solution and gel. The brand product (Condylox) has also seen production fluctuations.
• Periodic FDA shortage listings: Podofilox has appeared intermittently on FDA drug shortage databases, though not consistently. The reality at the pharmacy level has often been worse than official listings suggest.
• Supply chain fragility: As a low-volume specialty product, Podofilox is particularly vulnerable to raw material disruptions, manufacturing delays, and distribution bottlenecks.
• No new entrants: There have been no significant new manufacturers entering the Podofilox market, keeping supply constrained.

Prescribing Implications

The supply challenges present several practical issues for prescribers:

Prescription Fulfillment Delays

Patients may experience delays of days to weeks in filling Podofilox prescriptions. Some patients abandon treatment entirely when they can't find the medication promptly. Consider proactively discussing backup options at the time of prescribing.

Formulation Availability

The two formulations — 0.5% topical solution and 0.5% gel — may not be equally available. If your patient can't find one formulation, the other may be in stock. Both are therapeutically equivalent for the treatment of external genital warts, though the gel may be preferred by some patients for ease of application.

Patient Communication

Setting expectations at the point of prescribing can reduce patient frustration. Consider informing patients that:

• Podofilox may require checking multiple pharmacies
• Real-time availability tools like Medfinder for Providers can help locate stock
• Alternative treatments are available if Podofilox can't be obtained

Current Availability Picture

Availability varies significantly by geography and pharmacy type:

• Chain pharmacies: Inconsistent stock. Many locations don't carry Podofilox routinely and must special-order it.
• Independent pharmacies: May have better access through alternative wholesalers.
• Compounding pharmacies: Can prepare Podofilox formulations when commercial products are unavailable, though this requires appropriate prescribing.
• Mail-order pharmacies: Some mail-order services maintain stock when retail pharmacies don't.

The most efficient way to check current availability is through real-time tools. Medfinder's provider platform allows you to quickly verify stock at pharmacies in your patient's area.

Cost and Access Considerations

Cost can be a barrier to treatment, particularly for uninsured or underinsured patients:

• Generic Podofilox: $80 to $250 cash price, depending on pharmacy
• Brand Condylox: $150 to $500+ without insurance
• With insurance: Most plans cover Podofilox, typically at Tier 2 or 3. Copays usually range from $10 to $75. Prior authorization is uncommon but may be required by some plans.

Patients without adequate coverage may benefit from:

• Prescription discount cards: GoodRx, SingleCare, and similar services can reduce costs significantly
• Patient assistance programs: NeedyMeds and RxAssist maintain databases of programs that may help qualifying patients
• Manufacturer programs: Limited availability for Podofilox specifically, but worth checking

For patient-facing cost guidance, direct patients to our savings guide for Podofilox.

Tools and Resources for Providers

Medfinder for Providers

Medfinder's provider platform offers real-time pharmacy stock data that can be integrated into your clinical workflow. Instead of having patients call pharmacy after pharmacy, you can quickly identify locations with current availability and direct patients accordingly.

FDA Drug Shortage Database

The FDA maintains a drug shortage database that can be checked for official shortage status. However, note that not all practical supply disruptions are captured in this database.

Clinical Decision Support

When Podofilox is unavailable, consider the following evidence-based alternatives:

• Imiquimod 5% cream (Aldara) or 3.75% cream (Zyclara): Immune response modifier. Patient-applied. Treatment duration up to 16 weeks.
• Sinecatechins 15% ointment (Veregen): Botanical preparation. Patient-applied. Treatment duration up to 16 weeks. Approved for external genital and perianal warts.
• Cryotherapy: Provider-applied liquid nitrogen. Repeat every 1-2 weeks.
• Trichloroacetic acid (TCA) 80-90%: Provider-applied. Repeat weekly as needed. Safe in pregnancy.

Looking Ahead

There are no indications that the Podofilox supply situation will resolve quickly. The fundamental issue — a small number of manufacturers serving a relatively small market — is structural and unlikely to change without new market entrants or policy interventions.

Providers should continue to:

• Maintain familiarity with alternative treatments
• Use real-time availability tools to assist patients
• Prescribe flexibly (e.g., noting both solution and gel formulations as acceptable)
• Educate patients about their options proactively

Final Thoughts

The Podofilox shortage is an inconvenience that adds complexity to the management of a common and treatable condition. By staying informed about the supply landscape, maintaining flexible prescribing practices, and leveraging modern availability tools like Medfinder for Providers, you can continue to ensure your patients receive effective treatment for external genital warts — even when their first-line medication is in short supply.

For patient-facing resources, refer patients to our articles on finding Podofilox in stock and alternative treatments.